Revefenacin

Revefenacin
Clinical data
Trade names	Yupelri
AHFS/Drugs.com	Monograph
MedlinePlus	a619009
License data	US DailyMed: Revefenacin;
Routes of; administration	Inhalation
ATC code	R03BB08 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	864750-70-9;
PubChem CID	11753673;
DrugBank	DB11855;
ChemSpider	9928376;
UNII	G2AE2VE07O;
KEGG	D10978;
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;
	InChI InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43); Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N;

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.^[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.^[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.^[3]

References